Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021.
Akoya reported the following preliminary financial results for the fourth quarter and full year 2021, which remain subject to quarter end closing adjustments:
Revenue for the fourth quarter of 2021 is expected to be between $16.0 million and $16.2 million, as compared to $12.9 million for the corresponding quarter of last year
For the fiscal year of 2021, revenue is expected to be between $54.8 million and $55.0 million, as compared to $42.4 million for fiscal year 2020
“The fourth quarter of 2021 was a record revenue quarter for Akoya and it demonstrates continued momentum in our business,” said Brian McKelligon, Chief Executive Officer. “We made significant progress in 2021 on a number of major initiatives, including our IPO in April, approximately 30% growth in revenues, nearly doubling the company’s headcount with specific emphasis on the commercial and R&D organizations, and announcement of our new 2022 product offerings at our inaugural Spatial Day on December 15, 2021. We enter 2022 with tremendous confidence in our strategy as we drive adoption of our spatial biology platforms to our research, translational and clinical customers.”
A link to a webcast replay of Akoya’s inaugural Spatial Day, which took place virtually on December 15, 2021, can be found below:
Akoya Spatial Day 2021 | Akoya (akoyabio.com)
https://finance.yahoo.com/news/akoya-announces-preliminary-financial-results-130000706.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.